Xtant Medical Holdings

XTNT

Market cap $79.8M

BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 2026 Musculoskeletal Conference, which is being held March 2, 2026, in New Orleans and virtually.

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont. , Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™.

BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that the company has completed its previously announced sale of certain non-core Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC, and its affiliates.

Xtant Medical Holdings, Inc. ( XTNT ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Sean Browne - President, CEO & Director Scott Neils - Chief Financial Officer Conference Call Participants Kevin Gardner Ryan Zimmerman - BTIG, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the Xtant Medical Third Quarter 2025 Financial Results. [Operator Instructions].

Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24 Previously Announced Sale of Certain Hardware Assets and OUS Businesses to Companion Spine Anticipated to Close by Year-End BELGRADE, Mont. , Nov. 10, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2025.

Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont. , Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.

BELGRADE, Mont. , Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the start of trading on Tuesday, November 11, 2025.

BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO, and Scott Neils, CFO, will be participating in the H.C.

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Scott C. Neils - Chief Financial Officer Sean E.

Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont. , Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025.